Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0040822 (
tremor
)
18,428
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
The aim of the present study was to evaluate the ability of D-Ala
2
GIP, a gastric inhibitory polypeptide (GIP) receptor agonist, to attenuate the behavioral phenotype of Parkinson's disease caused by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) administration in mice. In the behavioral studies, MPTP administration led to spontaneous locomotor activity deficits, impaired rotarod performance, akinesia, muscular rigidity and increased
tremor
amplitude, which was attenuated by pretreatment with D-Ala
2
GIP (50-100 nmol/kg, i.p.). This acute neuroprotective response by D-Ala
2
GIP was found to be blocked by a selective
GIP receptor
antagonist, (Pro
3
)GIP (50 nmol/kg, i.p.), indicating that the observed effects are mediated through
GIP receptor
mediated signaling pathway. Biochemical studies revealed that D-Ala
2
GIP reduced the brain malondialdehyde levels and enhanced the brain glutathione levels, thereby mitigating the MPTP-induced oxidative stress. MPTP administration resulted in reduction of the striatal concentration of dopamine and its metabolites, homovanillic acid (HVA) and 3, 4-Dihydroxyphenylacetic acid (DOPAC). Pretreatment with D-Ala
2
GIP attenuated the loss of striatal dopamine levels without affecting the normal dopamine catabolism. Thus, the observed effects in the MPTP-induced Parkinsonism model could be in part attributable to the antioxidant properties of D-Ala
2
GIP and enhanced turnover of dopamine in the nigrostriatal pathways in mouse brain. These findings together suggest that
GIP receptor
could be a therapeutic target in the management of symptoms of Parkinson's disease.
...
PMID:Effect of D-Ala
2
GIP, a stable GIP receptor agonist on MPTP-induced neuronal impairments in mice. 2836 9
